United Therapeutics
UTHR
400 hedge funds and large institutions have $6.44B invested in United Therapeutics in 2017 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 135 increasing their positions, 139 reducing their positions, and 32 closing their positions.
94% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 32
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
26% more capital invested
Capital invested by funds: $5.13B → $6.44B (+$1.31B)
7% more funds holding
Funds holding: 373 → 400 (+27)
0.49% more ownership
Funds ownership: 100.54% → 101.03% (+0.49%)
3% less repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 139
11% less call options, than puts
Call options by funds: $20.4M | Put options by funds: $23M
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$43.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.4M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$31.4M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$24.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$21.7M |
UTHR Hedge Fund Activity: Q4 2017 in Review
400 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2017, worth a combined $6.44B — up 26% from $5.13B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new UTHR positions and 32 closed out — a net gain of 30 holders — while 135 added to existing stakes and 139 trimmed.
The largest buyer was Skandinaviska Enskilda Banken (SEB), adding an estimated $47.1M. The largest seller was Morgan Stanley, cutting an estimated $43.6M.
- 400 institutional investors held United Therapeutics (UTHR) as of Q4 2017, up from 373 in Q3 2017.
- Funds reported $6.44B of United Therapeutics stock for Q4 2017, up 26% quarter-over-quarter.
- 62 funds opened new United Therapeutics positions in Q4 2017 and 32 closed out, a net change of +30 holders.
- The largest United Therapeutics buyer in Q4 2017 was Skandinaviska Enskilda Banken (SEB), an estimated $47.1M added.
- The largest United Therapeutics seller in Q4 2017 was Morgan Stanley, an estimated $43.6M sold.
Based on aggregated 13F filings for Q4 2017.